Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-26 @ 3:18 PM
NCT ID:
NCT07470151
Brief Summary:
A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. At the same time, the PK/PD characteristics of EVM18001 will be evaluated, preliminary efficacy will be observed, and related biomarkers and immunogenicity will be explored.
Detailed Description:
The main questions it aims to answer are:
* If EVM18001 is safe and tolerate in patients with active refractory autoimmune diseases (SLE, MG, and SSc)?
* What the recommended dose for subsequent treatment?
* What the PK/PD profiles of EVM18001 in patients with active refractory autoimmune diseases (SLE, MG, and SSc)?
* What the efficacy of EVM18001 in patients with active refractory autoimmune diseases (SLE, MG, and SSc)#
* What the biomarkers and immunogenicity of EVM18001 in treating of patients with active refractory autoimmune diseases (SLE, MG, and SSc)?
Participants will:
* Inform the investigator in a timely manner when unable to attend a visit.
* Report any changes in their health condition to the study doctor, including discomfort or other health issues during the screening period.
* Inform the study doctor of any other medications taken before and during the study; inform the study doctor before starting any new medications.
* Be informed of any medications which may be affected by the study drug that should not be used during the study.
* Agree to use effective contraception during the study and for 12 months after the last infusion of EVM18001EVM injection.
Study:
NCT07470151
Study Brief:
Protocol Section:
NCT07470151